New research has pinpointed the specific brain region and neuron type responsible for reducing anxiety using the psychedelic drug DOI, without triggering hallucinations. The study revealed that DOI targets serotonin2A receptors on parvalbumin-positive neurons in the ventral hippocampus, decreasing anxiety behaviors in animal models.
